

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司
NORTHEAST TIGER PHARMACEUTICAL CO., LTD.*
(A joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8197)

VOLUNTARY ANNOUNCEMENT COOPERATION FRAMEWORK AGREEMENT

This is a voluntary announcement made by Northeast Tiger Pharmaceutical Co., Ltd.* (the “**Company**”).

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on 16 March 2017, the Company entered into a cooperation framework agreement (the “**Cooperation Framework Agreement**”) with Xi’an Xiang Xun Technology Company Limited* (西安翔迅科技有限責任公司) (“**Xiang Xun**”).

Based on the mutual understanding on the big data industry and leveraging on their respective strengths, the Company and Xiang Xun entered into the Cooperation Framework Agreement so as to foster deeper strategic cooperation in the businesses of smart healthcare, smart education and smart city.

Major terms of the Cooperation Framework Agreement

The Cooperation Framework Agreement is for a term of five years commencing from the date of its execution.

Pursuant to the Cooperation Framework Agreement, the Company and Xiang Xun agreed as follows:

- (1) Xiang Xun possesses extensive technical expertise and system engineering experience in the areas of smart transportation, security electronics and measurement and control technologies and has a well-established product line, efficient quality management system and good after-sale services. The Company agreed to choose Xiang Xun to be its core supplier and designate Xiang Xun as the preferred provider of system integration technology and other related technologies and services on terms which are the same as those available to the Company in the market.

- (2) The Company possesses big data processing and application technologies and has experience in relation to big data for smart education, smart healthcare, smart elderly care and smart environmental protection, etc. Xiang Xun agreed to choose the Company to be its core supplier and designate the Company as the preferred provider of big data analysis service and other related products and services on terms which are the same as those available to Xiang Xun in the market.
- (3) The Company and Xiang Xun agreed to seek for potential cooperation opportunities in their respective business development in the future, cooperate to develop new projects based on the principles of mutual benefits and complementary advantages so as to enhance the economic benefits and overall competitiveness of each other.

General

Xiang Xun is a high-tech enterprise in Shaanxi Province of the People's Republic of China and is an integrated high-tech enterprise involved in the research and development, production, sales and services of smart transportation products.

To the best of the Directors' knowledge, information and belief and having made all reasonable enquiries, each of Xiang Xun and its ultimate beneficial owner(s) is an independent third party independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Hong Kong Stock Exchange Limited (the "GEM Listing Rules"))).

The Board wishes to emphasise that the terms of the Cooperation Framework Agreement only set out the cooperation intentions of the Company and Xiang Xun. The parties will enter into negotiations in relation to the details of the form of cooperation and further specific cooperation agreements will be entered into by the Company and Xiang Xun as appropriate. The Company will make further announcement(s) in respect of the cooperation projects in accordance with the GEM Listing Rules if and when required.

By order of the Board
東北虎藥業股份有限公司
Northeast Tiger Pharmaceutical Co., Ltd.*
Chairman
Wang Shaoyan

Beijing, the People's Republic of China, 16 March 2017

As at the date of this announcement, the executive Directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the non-executive Directors are Guo Aiqun and Cao Yang and the independent non-executive Directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the website of the GEM at <http://www.hkgem.com> for at least 7 days from the day of its posting and the Company’s website at <http://www.northeasttiger.com> from the date of this announcement.

** For identification purpose only*